MedCity News: Is too much money being invested in oncology?

“Between venture capitalists flush with cash and corporate mergers and acquisitions, money is gushing into oncology.

The $1 billion-plus invested in Grail is the grand example, but every week, another big deal is announced. After spending $12 billion on Kite, Gilead recently purchased Cell Design Labs for $567 million. So far in 2018, Tmunity Therapeutics brought in $100 million in Series A funding and Celgene put down $9 billion for Juno Therapeutics– and it’s only a month into the new year.”

Media Inquiries

Mark Corbae
Canale Communications